The determination of serum levels of antibodies against hepatitis B virus surface antigen (anti-HBs) after hepatitis B vaccination is currently the only simple test available to predict the decay of protection and to plan the administration of booster doses.
A total of 3085 vaccine recipients of plasma-derived and recombinant vaccine have been followed for 10 years to determine the kinetics of anti-HBs production and to construct a mathematical model which could efficiently predict the anti-HBs level decline.
The anti-HBs peak level was reached 68 days after the last dose of recombinant vaccine and 138 days after the last dose of plasma-derived vaccines.
The age of vaccinees negatively influenced the anti-HBs levels and also the time necessary to reach the anti-HBs peak.
A bilogarithmic mathematical model (log10 level, log1 time) of anti-HBs decay has been constructed on a sample of recombinant vaccine recipients and subsequently validated on different samples of recombinant or plasma-derived vaccine recipients.
Age, gender, type of vaccine (recombinant or plasma-derived). number of vaccine doses (three or four) did not influence the mathematical model of antibody decay.
The program can be downloaded at the site : http :/www2. stat. unibo. it/palareti/vaccine. htm.
Introducing an anti-HBs determination obtained after the peak, the program calculates a prediction of individual anti-HBs decline and allows planning of an efficient booster policy.
Mots-clés Pascal : Hépatite virale B, Virose, Infection, Vaccination, Anticorps, Cinétique, Modèle mathématique, Antigène HBs, Vaccin, Protéine recombinante, Internet, Site, Algorithme, Aide décision, Calendrier vaccination, Immunothérapie, Immunisation active, Homme, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : Viral hepatitis B, Viral disease, Infection, Vaccination, Antibody, Kinetics, Mathematical model, Hepatitis B surface antigen, Vaccine, Recombinant protein, Internet, Site, Algorithm, Decision aid, Vaccination schedule, Immunotherapy, Active immunization, Human, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0221088
Code Inist : 002B05C02G. Création : 16/11/1999.